Phoenix Pharmacologics (Lexington, Ky.) started an Italian open-label Phase III trial of its recombinant pegylated arginine deiminase (ADI-PEG 20) targeted enzyme therapy in 80 patients with terminal liver cancer. The trial, which will measure survival...
Phoenix Pharmacologics Inc. Lexington, Ky. Technology: Recombinant proteins and peptides Disease focus: Cancer, inflammation Clinical status: Phase II Founded: 1996 by Mike Clark and John Bomalaski Corporate partners: TDW University collaborators: None Employees: 18 Funds...
Phoenix Pharmacologics Inc. is trying to expand the uses of two clinically validated enzymatic therapy concepts. The company's lead product, recombinant pegylated arginine deiminase (ADI-PEG 20), applies the concept behind the anti-cancer enzyme therapy asparaginase...
Phoenix Pharmacologics (Lexington, Ky.) started an Italian open-label Phase III trial of its recombinant pegylated arginine deiminase (ADI-PEG 20) targeted enzyme therapy in 80 patients with terminal liver cancer. The trial, which will measure survival...
Phoenix Pharmacologics Inc. Lexington, Ky. Technology: Recombinant proteins and peptides Disease focus: Cancer, inflammation Clinical status: Phase II Founded: 1996 by Mike Clark and John Bomalaski Corporate partners: TDW University collaborators: None Employees: 18 Funds...
Phoenix Pharmacologics Inc. is trying to expand the uses of two clinically validated enzymatic therapy concepts. The company's lead product, recombinant pegylated arginine deiminase (ADI-PEG 20), applies the concept behind the anti-cancer enzyme therapy asparaginase...
